Alzheimer's Disease
AltPep secures $53M in funding to advance novel Alzheimer’s, Parkinson’s therapeutics
A Seattle-based biotechnology company announced completion of a $52.9 million Series B financing round to advance clinical trials of novel therapeutics for Alzheimer’s and Parkinson’s diseases.
Alzamend identifies maximum tolerated dose of lithium treatment for neurological disorders
Topline data from a phase 2a, multiple ascending dose study identified a maximum tolerated dose for development of AL001, an investigational lithium-delivery system, according to a press release from manufacturer Alzamend Neuro.
VIDEO: Lifestyle modifications key for prevention of Alzheimer’s disease
SAN FRANCISCO — At least 30% of Alzheimer’s disease cases can be prevented through lifestyle modifications, Rajesh R. Tampi, MD, MS, DFAPA, said in this Healio video from the American Psychiatric Association Annual Meeting.
FDA committee says Leqembi shows benefits in early Alzheimer’s
The FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted on June 9 that Leqembi showed clinical benefit in early Alzheimer’s disease, the Alzheimer’s Drug Discovery Foundation said in a press release.
CMS announces plan for Medicare coverage of approved Alzheimer's drugs
Medicare will cover drugs that may slow the progression of Alzheimer’s disease if granted traditional approval from the FDA, according to a press release from CMS.
Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months
BOSTON — Treatment with Leqembi reduced markers of amyloid and tau in patients with early Alzheimer’s disease and slowed cognitive and functional decline at 18 months, according to data at the American Academy of Neurology annual meeting.
Donanemab slows cognitive, functional decline in early Alzheimer’s
Donanemab slowed cognitive and functional decline in early Alzheimer’s disease, according to the results of a phase 3 study.
When considering monoclonal antibodies for Alzheimer’s disease, ‘caution is key’
SAN DIEGO — Two monoclonal antibodies are now available in the U.S. as disease-modifying therapies for early Alzheimer’s disease, but there are concerns about the drugs that physicians must be aware of before prescribing them, an expert said.
Phase 2a clinical trial targeting anxiety, depression in Alzheimer’s begins
A biotech company has started the first clinical trial of a sublingual formulation targeting anxiety and depression in people with Alzheimer’s disease, according to a press release.
Online tool predicts personalized dementia, Alzheimer’s risk
An online prediction tool may help identify users’ risks for dementia and Alzheimer’s disease based on individual factors, according to a study published in The Journal of Prevention of Alzheimer’s Disease.